# Lecture 13: Pain 3 - Opioids & Pain Pathways

## Definitions

| Term | Definition |
|------|------------|
| **Opium** | From the poppy plant |
| **Opiate** | Natural alkaloids in opium resin |
| **Opioid** | Any drug acting on opioid receptors (includes opiates and synthetics) |
| **Narcotic** | Loosely applied to controlled psychoactive drugs |

---

## Pain Pathways

### Sensory Fibers

| Fiber Type | Speed | Stimulus | Sensation |
|------------|-------|----------|-----------|
| **A-delta** | Fast | Mechanical, Temperature (cold) | Sharp, well-localized pain |
| **C fibers** | Slow (unmyelinated) | Mechanical, Temperature (hot) | Dull, diffuse pain |

### Ascending Pathway (Spinothalamic Tract)

**Two divisions**:
1. **Anterior** - Crude touch and pressure
2. **Lateral** - Pain and temperature

**Pathway**:
1. Primary afferent → Dorsal horn of spinal cord
2. Crosses midline → Ascends in anterolateral system (ALS)
3. Gives branches to:
   - **Reticular formation** → Arousal/awareness
   - **Parabrachial nucleus** (pons) → Fear/anger via amygdala
   - **Hypothalamus** → Autonomic function
4. Synapses in **thalamus**
5. Projects to:
   - **Cingulate gyrus/Anterior insular cortex** → Emotion regulation
   - **Somatosensory cortex** → Pain perception

---

## Opioid Receptors

### Types
- **Mu (μ)** - Primary target for analgesia
- **Kappa (κ)** - Dysphoria, sedation
- **Delta (δ)** - Modulation

### Location
- High density in **dorsal root ganglion**
- Present in both ascending AND descending pain pathways

---

## Opioid Effects

### CNS Effects
1. **Analgesia**
2. **Sedation**
3. **Respiratory depression** (decreased rate)
4. **Miosis** (pinpoint pupils)

### GI Effects
1. **Constipation**
2. **Nausea/Vomiting**

### Other Effects
1. Pruritus
2. Endocrine dysfunction
3. Immune suppression

### Psychological Effects
1. Dependence
2. Withdrawal
3. Addiction
4. Delirium

---

## Opioid Classifications

### Full Agonists
- Morphine, Hydromorphone, Oxycodone, Fentanyl, Methadone

### Partial Agonist
- **Buprenorphine** (prototypical)

### Full Antagonists
| Drug | Use |
|------|-----|
| **Naloxone** | Overdose rescue (short-acting) |
| **Naltrexone** | Long-term treatment (opioid use disorder) |

---

## Opioid Pharmacokinetics

### Metabolism
| Drug | Pathway | Clinical Concern |
|------|---------|------------------|
| **Morphine** | UGT (glucuronidation) | Buildup in renal failure → overdose |
| **Codeine, Tramadol** | CYP2D6 | Poor/ultra-rapid metabolizers affect efficacy |
| **Fentanyl, Methadone** | CYP3A4 | Drug interactions (macrolides inhibit CYP3A4 → buildup) |
| **Meperidine** | Hepatic → Normeperidine | Normeperidine causes **seizures** |

### Drug Interactions
- **SSRIs** inhibit CYP2D6 → affects codeine/tramadol conversion
- **Macrolide antibiotics** inhibit CYP3A4 → increases fentanyl/methadone levels

---

## Opioid Overdose

### Signs & Symptoms
- Sedation
- **Respiratory depression**
- **Pinpoint pupils (miosis)**

### Three Waves of Opioid Deaths
1. Prescription opioids (1990s)
2. Heroin (2010)
3. Synthetic opioids - fentanyl (2013+)

### Treatment
- **Naloxone** (Narcan)
- Note: Synthetic opioids may not show on urine drug screens

---

## Adjuvant Analgesics for Pain

### Tricyclic Antidepressants (TCAs)
| Use | Mechanism |
|-----|-----------|
| Neuropathic pain | Noradrenergic effects |

### SNRIs
| Drug | Indications |
|------|-------------|
| **Duloxetine** | FDA approved for fibromyalgia, diabetic neuropathy, chronic pain |

### Gabapentinoids
| Drugs | Use | Mechanism |
|-------|-----|-----------|
| **Gabapentin, Pregabalin** | Fibromyalgia, diabetic neuropathy | Presynaptic calcium channel modulation (α2δ subunit) |
